ChromaDex (NASDAQ: CDXC)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-02 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.080 | -0.090 | -0.0100 | ||||
REV | 18.650M | 16.732M | -1.918M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ChromaDex (NASDAQ: CDXC) through any online brokerage.
Other companies in ChromaDex’s space includes: Harvard Bioscience (NASDAQ:HBIO), Codex DNA (NASDAQ:DNAY), Personalis (NASDAQ:PSNL), IsoPlexis (NASDAQ:ISO) and Quoin Pharmaceuticals (NASDAQ:QNRX).
The latest price target for ChromaDex (NASDAQ: CDXC) was reported by Oppenheimer on Tuesday, August 16, 2022. The analyst firm set a price target for 0.00 expecting CDXC to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for ChromaDex (NASDAQ: CDXC) is $1.64 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for ChromaDex.
ChromaDex’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for ChromaDex.
ChromaDex is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.